Morgan Stanley Maintains Overweight on Axonics, Lowers Price Target to $69
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Cecilia Furlong has maintained an Overweight rating on Axonics (NASDAQ:AXNX) but lowered the price target from $76 to $69.

October 31, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axonics' price target has been lowered by Morgan Stanley from $76 to $69, although the Overweight rating is maintained.
The news is directly about Axonics. While the Overweight rating indicates that Morgan Stanley still sees the stock as a good investment, the lowering of the price target could indicate a slightly less optimistic outlook. This could potentially have a neutral to slightly negative impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100